The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Advances in MCL treatment: insights from TRIANGLE, the changing role of SCT & novel targeted agents
In this discussion, leading experts Martin Dreyling, MD, LMU University Hospital Munich, Munich, Germany, and Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, discuss key advances in mantle cell lymphoma (MCL) treatment. They share insights into the shift away from intensive chemotherapy and autologous stem cell transplantation (autoSCT), highlighting findings from the TRIANGLE trial (NCT02858258). The experts also outline their current approaches to treating frontline and relapsed MCL, commenting on the evolving role of novel agents such as BTK inhibitors and CAR T-cells. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
